January 21st 2025
RP1 with nivolumab elicited an ORR of 38.7% with an acceptable safety profile in patients with advanced melanoma who progressed on anti–PD-1 therapy.
Positive Efficacy Data Found With Lifileucel TIL Therapy for Pretreated Advanced Melanoma
April 11th 2021Lifileucel (LN-144), the tumor-infiltrating lymphocyte therapy, showed a positive objective response rate with the median duration of response not yet reached after more than 28 months of follow-up in patients with advanced melanoma.
Adjuvant Nivolumab Plus Ipilimumab Combo For Late-Stage Melanoma Did Not Meet RFS End Point
April 11th 2021The combination adjuvant treatment of ipilimumab plus nivolumab did not meet the dual primary endpoints of the phase 3 CheckMate-915 trial, failing to improve relapse-free survival in the intent-to-treat and PD-L1 of less than 1% populations.
Adjuvant Immunotherapy Produced Survival Benefit for Patients With High-Risk Stage II Melanoma
March 23rd 2021Adjuvant immunotherapy treatment was associated with a significant survival benefit for patients with stage II melanoma in a study presented at the Society of Surgical Oncology 2021 International Conference on Surgical Cancer Care.
Study Identifies Shift in Incidence of Second Primary Cancers in Patients with Metastatic Melanoma
January 27th 2021During the age of systemic immunotherapy, investigators observed a change in the incidence of second primary cancers after metastatic melanoma that included solid tumor and hematologic malignancies.
FDA Grants Orphan Drug Designation to PVSRIPO for Treatment of Advanced Melanoma
January 22nd 2021The novel viral immunotherapy PVSRIPO is designed to stimulate a patient’s innate and adaptive immune system to promote an antitumor response and establish long-term immunologic memory to help keep their cancer at bay.
Phase 3 IMCgp100-202 Trial of Tebentafusp Shows Promise for Metastatic Uveal Melanoma
November 23rd 2020The clinical trial of tebentafusp (IMCgp100) versus investigator’s choice in metastatic uveal melanoma met its pre-defined boundaries for statistical significance of the primary end point of overall survival in its first pre-planned interim analysis.
ctDNA May Be Reliable Predictor of Outcomes with First-Line Immunotherapy for Melanoma
October 19th 2020Pretreatment circulating tumor DNA was found to be a reliable indicator of patient outcome for those with metastatic melanoma in the first-line immune checkpoint inhibitor (ICI) treatment setting, but not in the second-line setting.
Topical Immunosuppressants Drugs Don’t Increase Risk of Common Skin Cancers, Despite Warning Labels
October 5th 2020A study published in JAMA Dermatology determined that topical immunosuppressant medications used to treat adult patients with atopic dermatitis do not increase the risk of common forms of cancer despite warning labels on the packaging.